A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VOYAGE 2
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Jul 2017 According to a Janssen Biotech media release, the US FDA approved TREMFYA (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The approval was based on on results from VOYAGE 1, VOYAGE 2 and NAVIGATE studies.
    • 11 Jul 2017 Planned End Date changed from 17 Nov 2018 to 10 Jul 2020.
    • 05 Apr 2017 Planned End Date changed from 1 Jun 2018 to 17 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top